Back to Feed
ClinicalTrials.gov|Clinical Trial
P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma
Poseida Therapeutics, Inc.
Abstract
Phase 1 study comprised of open-label, dose escalation, multiple cohorts of P-BCMA-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed / refractory Multiple Myeloma (RRMM). Phase: PHASE1 Status: RECRUITING Conditions: Multiple Myeloma Interventions: P-BCMA-ALLO1 CAR-T cells; Rimiducid; Methotrexate
Keywords
Multiple Myeloma